First report of a glycosaminoglycan‐xylopyranan from the buccinid gastropod mollusk Babylonia spirata attenuating proinflammatory 5‐lipoxygenase

Chakraborty, Kajal and Salas, Soumya (2019) First report of a glycosaminoglycan‐xylopyranan from the buccinid gastropod mollusk Babylonia spirata attenuating proinflammatory 5‐lipoxygenase. Journal of Food Biochemistry. pp. 1-9. ISSN 1745–4514

Text Journal of Food Biochemistry_2019_Kajal Chakraborty_First report of a glycosaminoglycan‐xylopyranan from the buccinid gastropod mollusk Babylonia spirata.pdf Restricted to Registered users only Download (889kB) | Request a copy

Abstract

A previously undescribed xylated glycosaminoglycan characterized as β‐D‐ Xylop(1 → 3)‐(⋯ → 4)‐GlcpA(1 → 3)‐GlcpNAc(1 → ⋯) was purified from the buccinid gastropod Babylonia spirata and was evaluated for pharmacological properties using different in vitro models. The glycosaminoglycan‐xylopyranan displayed prospective free radical quenching activities (IC50 < 0.7 mg/ml), whereas it exhibited potentially greater attenuation against the inductive proinflammatory enzyme 5‐lipoxygenase (5‐LOX, IC50 0.36 mg/ml) than the synthetic nonsteroidal anti‐inflammatory drug as‐ pirin (0.42). Gel permeation chromatography analysis specified the average molecular mass of the purified polysaccharide to be 231.88 kDa. The linkage sites, anomeric configuration, and the sequence of sugar residues of the purified xylated glycosami‐ noglycan were attributed by the inter‐residue correlation obtained via two‐dimen‐ sional nuclear resonance spectroscopic techniques. The results specified that the studied compound was composed of GlcpA(1 → 3)‐GlcpNAc (1 → ⋯) disaccharide repeating unit in the glycosaminoglycan backbone, with the xylose residues branch‐ ing as C‐3 substituents of the GlcpA. .

Actions (login required)

View Item